Medicare to negotiate price of Ozempic, Wegovy weight-loss drugs
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
Ozempic among drugs selected for Medicare price negotiations as Biden exits
Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before President-elect Donald Trump takes office.
Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
The list includes Novo Nordisk’s blockbuster diabetes injection Ozempic, weight loss shot Wegovy and diabetes pill Rybelsus, which are considered one product.
Ozempic tops new Medicare price negotiation list
The list of 15 drugs ( up from 10 in 2023) includes four oncology drugs, three drugs targeting diabetes, two focused on COPD, and two drugs for IBS. The list also includes the first psychiatric medicine to be included in price negotiation, Abbvie's Vraylar.
Ozempic, Wegovy included in next round of Medicare price negotiations with drug makerss
Fifteen new drugs including the Ozempic will be included in Medicare's next round of price negotiation with drug makers, the Biden administration announced Friday. Ozempic, used to treat Type 2 diabetes and obesity, is manufactured by Novo Nordisk.
Medicare announces 15 new drugs up for price negotiations, including Ozempic
The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, which includes Ozempic.
Medicare targets popular weight loss drugs Ozempic, Wegovy for price negotiations
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.
US targets Novo Nordisk's Ozempic and Wegovy for Medicare price talks
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday. Other drugs on the list include Pfizer's cancer drugs Ibrance and Xtandi,
Novo’s Wegovy Trails Lilly’s Zepbound in Higher-Dose Study
Raising the dose of Novo Nordisk A/S’s obesity drug Wegovy helped patients shed more pounds in a trial while still falling ...
Oral Ozempic and a ‘miracle’ pill imitating the keto diet – a new era of weight loss is here
The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they ...
FiercePharma1h
Novo's semaglutide among 2nd batch of drugs selected for IRA price negotiations
The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...
Eli Lilly's weight loss pill could get federal approval by early next year
Eli Lilly & Co. ( LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026.
24/7 Wall St. on MSN2d
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?
Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
STAT1h
High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...